What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?

Nakafero, Georgina; Grainge, Matthew J; Card, Tim; Mallen, Christian D; Zhang, Weiya; Doherty, Michael; Taal, Maarten W; Aithal, Guruprasad P; Abhishek, Abhishek

doi:10.1093/rheumatology/keab254

All Outputs (3)

Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum (2022)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Riley, R., Van Der Windt, D., …Abhishek, A. (2022). Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. Rheumatology Advances in Practice, 6(2), Article rkac046. https://doi.org/10.1093/rap/rkac046

Objective: The aim was to examine the incidence and pattern of MMF discontinuation associated with abnormal monitoring blood-test results. Methods: Data from people prescribed MMF for common inflammatory conditions in the Clinical Practice Research D... Read More about Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum.

Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Taal, M. W., Aithal, G. P., Zhang, W., …Abhishek, A. (2022). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology, 61(7), 2783-2791. https://doi.org/10.1093/rheumatology/keab790

OBJECTIVE: To develop and validate a prognostic model for LEF discontinuation with abnormal blood test results. METHODS: Data from the Clinical Practice Research Datalink Gold and Aurum were used for model development and external validation, respect... Read More about Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline? (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Zhang, W., Doherty, M., …Abhishek, A. (2021). What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. Rheumatology, 60(12), 5785-5794. https://doi.org/10.1093/rheumatology/keab254

Objectives: To examine incidence of treatment changes due to abnormal blood-test results and, to explore rates of treatment changes due to liver, kidney and haematological blood-test abnormalities in autoimmune rheumatic diseases (AIRD) treated with... Read More about What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?.